LeMaitre Vascular (NASDAQ:LMAT) had its "outperform" rating reaffirmed by analysts at Barrington Research. They now have a $95.00 price target on the stock.
LeMaitre Will Announce Fourth Quarter 2025 Earnings Results February 25, 2026
Is LeMaitre Vascular, Inc. (NASDAQ:LMAT) Expensive For A Reason? A Look At Its Intrinsic Value [Yahoo! Finance]
Do LeMaitre Vascular's (NASDAQ:LMAT) Earnings Warrant Your Attention? [Yahoo! Finance]
LeMaitre Vascular (NASDAQ:LMAT) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.